GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Debt-to-EBITDA

Insmed (Insmed) Debt-to-EBITDA : -1.85 (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Insmed's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $10.6 Mil. Insmed's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,193.4 Mil. Insmed's annualized EBITDA for the quarter that ended in Dec. 2023 was $-650.0 Mil. Insmed's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.85.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Insmed's Debt-to-EBITDA or its related term are showing as below:

INSM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.63   Med: -1.33   Max: -0.22
Current: -1.82

During the past 13 years, the highest Debt-to-EBITDA Ratio of Insmed was -0.22. The lowest was -2.63. And the median was -1.33.

INSM's Debt-to-EBITDA is ranked worse than
100% of 278 companies
in the Biotechnology industry
Industry Median: 1.355 vs INSM: -1.82

Insmed Debt-to-EBITDA Historical Data

The historical data trend for Insmed's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Debt-to-EBITDA Chart

Insmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.83 -1.62 -1.60 -2.63 -1.82

Insmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.08 -2.14 -1.33 -2.19 -1.85

Competitive Comparison of Insmed's Debt-to-EBITDA

For the Biotechnology subindustry, Insmed's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Insmed's Debt-to-EBITDA falls into.



Insmed Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Insmed's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.642 + 1193.352) / -660.177
=-1.82

Insmed's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(10.642 + 1193.352) / -650.016
=-1.85

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Insmed  (NAS:INSM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Insmed Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Insmed's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed (Insmed) Business Description

Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Executives
Flammer Martina M.d. officer: Chief Medical Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett officer: Chief Commercial Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise officer: Chief Commercial Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith officer: General Counsel, Senior VP 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis officer: President & CEO 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole officer: Chief People Strategy Officer INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano officer: Chief Compliance Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari officer: General Counsel & Secretary 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807